CRISPR Therapeutics (NasdaqGM:CRSP) FY Conference Transcript

Summary of CRISPR Therapeutics FY Conference Call Company Overview - Company: CRISPR Therapeutics (NasdaqGM:CRSP) - Date: March 02, 2026 - Key Speaker: Samarth Kulkarni, Chairman and CEO Core Industry Insights - Transition Focus: CRISPR is shifting from a technology-backed company to a disease-backed company, emphasizing a diverse pipeline beyond its lead product, Casgevy [3][4] - Pipeline Value: Approximately one-third of the company's value is attributed to Casgevy, with another third from promising Phase 1 assets (CTX310, CTX320, CTX611) [4] - Future Programs: By mid-2027, CRISPR anticipates data for six programs across more than six indications beyond Casgevy [4] Key Business Segments - Cardiovascular: - Programs include CTX310, CTX611, and CTX340 targeting refractory hypertension [5][6] - Autoimmune: - Focus on CTX320 and additional siRNA targets in the autoimmune space [5][6] - Other Areas: - Development in Type One diabetes and oncology [6] Casgevy Sales and Market Dynamics - 2025 Sales: Casgevy achieved over $100 million in sales for 2025, with expectations for continued growth in 2026 due to strong patient demand [7][8] - Patient Initiations: Increased from approximately 100 in 2024 to over 300 in 2025, with expectations for further growth in 2026 [7] - Revenue Timing: Revenue growth is anticipated as more patients are initiated and treatment sites become fully productive [9] Profitability and Investment - Peak Spending: 2025 is expected to be the peak year of spending for the Casgevy franchise, with a focus on investments in gentler conditioning agents and in vivo HSC delivery [10][11] - Profitability Outlook: While the timeline for profitability is uncertain, CRISPR is committed to driving towards it through strategic investments [10][11] Clinical Programs and Data Updates - CTX310 (ANGPTL3): - Early data shows an 80% reduction in ANGPTL3, leading to nearly 50% reduction in LDL and 60% in triglycerides [12][13] - Focus on specific patient populations for further data and potential regulatory discussions [15][16] - CTX320 and CTX321 (Lp(a)): - Awaiting Horizon data to inform the next steps in development, with CTX320 showing a 73% reduction in Lp levels [18][19] - CTX340 (Hypertension): - Initial dose escalation data expected soon, with promising preclinical results showing nearly 50% reduction in blood pressure [24][25] Safety and Regulatory Considerations - Safety Profile: CRISPR emphasizes the safety of its gene editing platform, with minor increases in liver function tests (LFTs) being self-resolving [22][23] - Regulatory Support: There is a positive regulatory environment for gene editing technologies, which are viewed as a future solution for curing diseases [22] SyNTase Technology - New Technology: SyNTase allows for precise editing at high efficiencies, with initial focus on A1AT indication [27][28] - Potential Impact: A1AT gene editing is expected to provide significant improvements in patient outcomes compared to existing therapies [29][30] siRNA Collaboration - Partnership with Sirius: CRISPR is collaborating on a Factor XI siRNA program, leveraging advanced technology to create durable and potent siRNAs [31][32] - Market Potential: The Factor XI program targets significant markets, including secondary stroke prevention [35][36] ZUGA Cell and CAR T Developments - ZUGA Cell: Positioned as a strong asset in the portfolio, with potential in both oncology and autoimmune indications [41][42] - In Vivo CAR T: CRISPR is exploring in vivo CAR T technologies, with promising early data and interest from pharmaceutical companies [43][44] Conclusion - CRISPR Therapeutics is strategically positioning itself for growth through a diverse pipeline, strong partnerships, and innovative technologies, with a focus on addressing significant unmet medical needs across various therapeutic areas.